XBI Rallies 34% as Biotech Sector Sees Broad Comeback

A Sector Reawakens

Biotech stocks are having their strongest stretch in years, with the SPDR S&P Biotech ETF (XBI) climbing roughly 34% since March on the back of a wave of M&A activity and positive clinical trial results, prompting at least one upgrade call urging investors to buy into the rally now 1. The surge has been broad enough to ripple across the wider market: on days when biotech shares soared, tech futures rose in sympathy even as AI stocks and software names lagged behind, suggesting money is rotating out of the most crowded trades and into previously beaten-down healthcare names 6.

Who's Benefiting

The bounceback is lifting more than just the big-name drugmakers. JPMorgan flagged Charles River Laboratories, a contract research organization that supports drug development, as a stock positioned to keep rallying alongside the broader biotech recovery following its latest earnings report 2. Fund managers are also capitalizing on the trend — the Franklin Biotechnology Discovery fund has posted a 13% annualized return over five years, more than double the 5.3% return of the benchmark biotech index ETF, underscoring how selective stock-picking within the sector has outperformed passive exposure 5. Moderna, meanwhile, delivered one of the most dramatic individual storylines: favorable late-stage trial results for a cancer vaccine helped restore billionaire status to one of the company's co-founders, a sign of how a single clinical win can reshape personal and corporate fortunes almost overnight 8.

Innovation, Scrutiny, and Policy Crosscurrents

Not all the news is celebratory. Reporting on Huidagene has raised questions from experts about the company's disclosure practices following a patient death, a reminder that clinical setbacks and transparency concerns remain very real risks even in a hot market 3. Separately, coverage of Merck and Moderna's mRNA cancer vaccine work, along with speculation about a potential nominee to lead the FDA, points to a regulatory environment in flux 3. That tension is echoed in commentary arguing that bureaucratic delays at the FDA are hampering American leadership in regenerative medicine, with critics warning that sluggish approval pathways risk ceding ground to international rivals, particularly China 7. Forward-looking market trackers are already framing 2026 as a pivotal year for biotech and pharma, promising continued focus on FDA approvals, trial readouts, and other market-moving catalysts 4.

The Fringes of Biotech Innovation

At the more experimental edge of the industry, Australian biotech firm Cortical Labs, working with Singapore's National University and DayOne, has launched a data center prototype powered by roughly 4 million living human neurons, which require feeding every three days 9. While far removed from Wall Street's earnings calendars, the project illustrates the sector's expanding definition — one that now stretches from conventional drug trials and ETF flows to biological computing.

What It Means

Taken together, the coverage suggests biotech's rally is being driven by genuine fundamentals — trial successes, M&A appetite, and strong fund performance — even as disclosure controversies and regulatory friction serve as reminders that the sector's risks haven't disappeared alongside its returns.